Outcome of Pediatric Thromboembolic Disease: A Report from the Canadian Childhood Thrombophilia Registry.
MONAGLE, PAUL; ADAMS, MARGARET; MAHONEY, MICHAEL; ALI, KAISER; BARNARD, DOROTHY; BERNSTEIN, MARK; BRISSON, LINDA; DAVID, MICHELE; DESAI, SUNIL; SCULLY, MARIE-FRANCIS; HALTON, JACQUELINE; ISRAELS, SARA; JARDINE, LAWRENCE; LEAKER, MICHAEL; McCUSKER, PATRICIA; SILVA, MARIANNA; WU, JOHN; ANDERSON, RON; ANDREW, MAUREEN; MASSICOTTE, M. PATRICIA
47(6):763-766, June 2000.
The outcome for children with deep vein thrombosis (DVT) and pulmonary embolism (PE) is unknown. An understanding of morbidity and mortality of DVT/PE is crucial to the development of rational treatment protocols. The Canadian Childhood Thrombophilia Registry has followed 405 children aged 1 mo to 18 y with DVT/PE for a mean of 2.86 y (range, 2 wk to 6 y) to assess outcome. The all-cause mortality was 65 of 405 children (16%). Mortality directly attributable to DVT/PE occurred in nine children (2.2%), all of whom had central venous line-associated thrombosis. Morbidity was substantial, with 33 children (8.1%) having recurrent thrombosis, and 50 children (12.4%) having postphlebitic syndrome. Recurrent thrombosis and postphlebitic syndrome were more common in older children, although deaths occurred equally in all age groups. The incidence of recurrent thrombosis and postphlebitic syndrome are likely underestimated because of difficulties in diagnosis, especially in younger children. The significant mortality and morbidity found in our study supports the need for international multicenter randomized clinical trials to determine optimal prophylactic and therapeutic treatment for children with DVT/PE.
(C) International Pediatrics Research Foundation, Inc. 2000. All Rights Reserved.